Patents by Inventor Peng-Cheng LU

Peng-Cheng LU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11370774
    Abstract: Disclosed are compounds of formulae I and II, and pharmaceutically acceptable salts and prodrugs thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.
    Type: Grant
    Filed: March 16, 2021
    Date of Patent: June 28, 2022
    Assignee: BioCryst Pharmaceuticals, Inc.
    Inventors: Pravin L. Kotian, Yarlagadda S. Babu, Weihe Zhang, Peng-Cheng Lu, Minwan Wu, Wei Lv, Trung Xuan Nguyen, Zhao Dang, Venkat R. Chintareddy, V. Satish Kumar, Krishnan Raman
  • Publication number: 20210221786
    Abstract: Disclosed are compounds of formulae I and II, and pharmaceutically acceptable salts and prodrugs thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.
    Type: Application
    Filed: March 16, 2021
    Publication date: July 22, 2021
    Inventors: Pravin L. Kotian, Yarlagadda S. Babu, Weihe Zhang, Peng-Cheng Lu, Minwan Wu, Wei Lv, Trung Xuan Nguyen, Zhao Dang, Venkat R. Chintareddy, V. Satish Kumar, Krishnan Raman
  • Patent number: 11021458
    Abstract: Disclosed are compounds of formulae I and II, and pharmaceutically acceptable salts and prodrugs thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.
    Type: Grant
    Filed: July 15, 2019
    Date of Patent: June 1, 2021
    Assignee: BioCryst Pharmaceuticals, Inc.
    Inventors: Pravin L. Kotian, Yarlagadda S. Babu, Weihe Zhang, Peng-Cheng Lu, Minwan Wu, Wei Lv, Trung Xuan Nguyen, Zhao Dang, Venkat R. Chintareddy, V. Satish Kumar, Krishnan Raman
  • Publication number: 20190345135
    Abstract: Disclosed are compounds of formulae I and II, and pharmaceutically acceptable salts and prodrugs thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.
    Type: Application
    Filed: July 15, 2019
    Publication date: November 14, 2019
    Inventors: Pravin L. Kotian, Yarlagadda S. Babu, Weihe Zhang, Peng-Cheng Lu, Minwan Wu, Wei Lv, Trung Xuan Nguyen, Zhao Dang, Venkat R. Chintareddy, V. Satish Kumar, Krishnan Raman
  • Patent number: 9399660
    Abstract: N-Substituted indenoisoquinoline compounds, and pharmaceutical formulations of N-substituted indenoisoquinoline compounds are described. Also described are processes for preparing N-substituted indenoisoquinoline compounds. Also described are methods for treating cancer in mammals using the described N-substituted indenoisoquinoline compounds or pharmaceutical formulations thereof.
    Type: Grant
    Filed: April 28, 2015
    Date of Patent: July 26, 2016
    Assignees: Purdue Research Foundation, NATIONAL INSTITUTES OF HEALTH (NIH)
    Inventors: Mark S. Cushman, Yves George Pommier, Peng-Cheng Lu, Christophe Marchand, Keli Agama
  • Publication number: 20150299246
    Abstract: N-Substituted indenoisoquinoline compounds, and pharmaceutical formulations of N-substituted indenoisoquinoline compounds are described. Also described are processes for preparing N-substituted indenoisoquinoline compounds. Also described are methods for treating cancer in mammals using the described N-substituted indenoisoquinoline compounds or pharmaceutical formulations thereof.
    Type: Application
    Filed: April 28, 2015
    Publication date: October 22, 2015
    Applicants: Purdue Research Foundation, THE GOVERNMENT OF THE USA AS REPRESENTED BY THE SECRETARY OF THE DEPT OF HEALTH AND HUMAN SERVICES
    Inventors: Mark S. CUSHMAN, Yves George POMMIER, Peng-Cheng LU, Christophe MARCHAND, Keli AGAMA